Annual Meeting of the Japanese Society of Toxicology
The 47th Annual Meeting of the Japanese Society of Toxicology
Session ID : S21-1
Conference information

Symposium 21
Comprehensive evaluation of pseudo exonic splicing mutations for drug development
*Masatoshi HAGIWARA
Author information
CONFERENCE PROCEEDINGS FREE ACCESS

Details
Abstract

Deep-intronic splicing mutations often cause inclusion of a pseudo exon, which in turn produces a premature stop codon leading to genetical inactivation. Number of disease-associated pseudo exonic mutations has dramatically increased because of recent advances in whole genome sequencing and transcriptome analysis. In contrast, mechanisms involved in pseudo exon recognition remain poorly explored. Understanding the mechanism of a disease-related splicing is crucial for finding an effective therapeutic strategy, as characterization of SMN2 exon 7 splicing led to development of Nusinersen for spinal muscular atrophy. In our hands, as previously demonstrated, splice-targeting therapeutics were achieved using small molecule compounds for genetic diseases such as Duchenne muscular dystrophy, NEMO deficiency syndrome, and familial dysautonomia, by targeting splicing regulators. Therefore, unveiling molecular mechanisms of pseudo exon recognition will provide a novel therapeutic strategy for pseudo exonic diseases.

Content from these authors
© 2020 The Japanese Society of Toxicology
Previous article Next article
feedback
Top